ConductScience.org, home

Paper32967006

SARS-CoV-2 vaccines in development.

Krammer F. Nature, 2020. Cited by 1,502 papers, by iCite.

Cite this record

ConductScience Library. SARS-CoV-2 vaccines in development. Papers, record 32967006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32967006

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
SARS-CoV-2 vaccines in development.
PubMed
Journal
Nature
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
1,502
iCite
Relative citation ratio, by iCite
70.2
iCite
Revised in PubMed
2026-10-10
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Krammer FFlorianhttps://orcid.org/0000-0003-4121-776X

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Coronavirus InfectionsMajor topic
Drug DevelopmentMajor topic
PandemicsMajor topic
Pneumonia, ViralMajor topic
Viral VaccinesMajor topic
Animals
COVID-19
COVID-19 Vaccines
Clinical Trials as Topic
Drug Industry
Humans
Immunity, Mucosal

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT04854876Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19BackgroundClinicalTrials.gov
NCT04944095Change in Antibody Levels Following SARS-CoV-2 (Covid-19) VaccinationsBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in33881342Infection and Inflammation of Genitourinary Tract.https://conductscience.org/library/papers/33881342

Source PubMed

Download CSV of comments and corrections

References87

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132785213Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.Nature2020https://conductscience.org/library/papers/32785213PubMed
226655630Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets.Vaccine2016https://conductscience.org/library/papers/26655630PubMed
332516797Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.Nature2020https://conductscience.org/library/papers/32516797PubMed
415650185Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event.J Virol2005https://conductscience.org/library/papers/15650185PubMed
532801356A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice.Cell Res2020https://conductscience.org/library/papers/32801356PubMed
632015507A pneumonia outbreak associated with a new coronavirus of probable bat origin.Nature2020https://conductscience.org/library/papers/32015507PubMed
732075877Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.Science2020https://conductscience.org/library/papers/32075877PubMed
832591393A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.J Immunol2020https://conductscience.org/library/papers/32591393PubMed
928807998Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.Proc Natl Acad Sci U S A2017https://conductscience.org/library/papers/28807998PubMed
1023261045High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season.Vaccine2013https://conductscience.org/library/papers/23261045PubMed
1133073694Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection.Emerg Microbes Infect2020https://conductscience.org/library/papers/33073694PubMed
1232789505Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.JAMA2020https://conductscience.org/library/papers/32789505PubMed
1333232870Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.EBioMedicine2020https://conductscience.org/library/papers/33232870PubMed
1432611917Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection.Indian J Med Res2020https://conductscience.org/library/papers/32611917PubMed
1532616673Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.Science2020https://conductscience.org/library/papers/32616673PubMed
1632731258ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.Nature2020https://conductscience.org/library/papers/32731258PubMed
1732722908Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.N Engl J Med2020https://conductscience.org/library/papers/32722908PubMed
1832702298Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.Lancet2020https://conductscience.org/library/papers/32702298PubMed
1917049691Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro.Vaccine2007https://conductscience.org/library/papers/17049691PubMed
2033139139NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.Vaccine2020https://conductscience.org/library/papers/33139139PubMed

See all 87 referencesDownload CSV of references

Cited by1,207

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,502 citations.

PMIDTitleJournalYearIn PapersSource
42975794Non-covalent inhibitors targeting SARS-CoV-2 3CLpro: structural insights and developmental landscape.Arch Pharm Res2026https://conductscience.org/library/papers/42975794PubMed
42903854Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms.Hlife2024https://conductscience.org/library/papers/42903854PubMed
42794550Evaluation of the Antiviral Activity of Cuscuta Extracts Against HSV-1, HSV-2 (ACV-Resistant Strain), HCoV229E and SARS-CoV-2.Int J Mol Sci2026https://conductscience.org/library/papers/42794550PubMed
42709284Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomed Microdevices2026https://conductscience.org/library/papers/42709284PubMed
42706242Dynamics of neutralizing antibody responses after trivalent XBB.1.5 booster vaccination: a 480-day longitudinal study.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42706242PubMed
42682883Host cell entry receptors as pharmacological targets in respiratory viral infections: from biology to clinical translation.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42682883PubMed
42646679
Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults.
Vaccines (Basel)2026https://conductscience.org/library/papers/42646679PubMed
42618711Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk.Sci Rep2026https://conductscience.org/library/papers/42618711PubMed
42506648Six Years of COVID-19: Lessons from Epidemiology, Vaccination Campaigns, Clinical Risk Stratification, and Thromboembolic Surveillance.Vaccines (Basel)2026https://conductscience.org/library/papers/42506648PubMed
42506597Emerging Viral Zoonoses: Epidemiology, Vaccination Strategies, and Implications for Global Public Health.Vaccines (Basel)2026https://conductscience.org/library/papers/42506597PubMed
42498827Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune mediated inflammatory disease.Pediatr Res2026https://conductscience.org/library/papers/42498827PubMed
42489461Respiratory mucosal vaccines for emerging viruses: promise and challenges.J Virol2026https://conductscience.org/library/papers/42489461PubMed
42467983The critical role of artificial intelligence and bioinformatics in accelerating peptide-based vaccine discovery for tackling global infectious diseases.Brief Bioinform2026https://conductscience.org/library/papers/42467983PubMed
42430655Eras of bioinformatics technologies from command-line interfaces to artificial intelligence (AI) chatbots.Brief Bioinform2026https://conductscience.org/library/papers/42430655PubMed
42371831Cytokine Profiles in Peripheral Blood Mononuclear Cells and Neutrophils following SARS-CoV-2 Vaccination: A Study from Kuwait.Med Princ Pract2026https://conductscience.org/library/papers/42371831PubMed
42347602
Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults.
Vaccines (Basel)2026https://conductscience.org/library/papers/42347602PubMed
42311421Nanotechnology-Enhanced Vaccines for Respiratory Infections: Opportunities and Challenges.Int J Nanomedicine2026https://conductscience.org/library/papers/42311421PubMed
42188806Immune Cell Signaling in Feline Infectious Peritonitis Virus Infection and Implications for Vaccine Design.Vaccines (Basel)2026https://conductscience.org/library/papers/42188806PubMed
42188772Intranasal Immunization with Live-Attenuated RSV-Vectored SARS-CoV-2 Vaccines Elicits Antigen-Specific Systemic and Mucosal Immunity and Protects Against Viral Challenge and Natural Infection.Vaccines (Basel)2026https://conductscience.org/library/papers/42188772PubMed
42181885Artificial intelligence for coordinating vaccine design, antiviral discovery, and real-world monitoring in the era of emerging and endemic viral threats.Front Pharmacol2026https://conductscience.org/library/papers/42181885PubMed

See all 1,207 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32967006

GET https://conductscience.org/api/papers/v1/32967006/references?page=2